Progestogen Experience Among Transgender Women and Gender Diverse Adults Assigned Male at Birth in the United States
Authors' conclusion
In the largest survey describing progestogen experience in E-GAHT to date, over half of TGD AMAB adults used progestogens. While most report satisfaction with use, further objective evidence on the benefits of progestogens is needed to clarify their clinical impact as part of E-GAHT.
Study context
- Population
- Transgender and gender diverse (TGD) adults AMAB with feminine/transfeminine or nonbinary gender identity in the United States, online cohort310 progestogen users
- Participants
- 543 participants
- Outcome
- Progestogen use patterns, initiation reasons, perceived impact, side effects and care satisfaction
Methodological detailsmixed-methods concurrent embedded design, online survey
- Mixed-methods concurrent embedded design
- Online survey
Main finding
As reported in the abstract
- Oral micronized progesterone
- 58.4%
- Rectal micronized progesterone
- 10.6%
- Oral medroxyprogesterone acetate
- 7.7%
- Breast development as reason for initiation
- 85.2%
- Perceived improvement in breast development
- 79.6%
- Perceived improvement in sense of femininity
- 81.3%
- Satisfied with progestogens
- 71.9%
Observational data: associations, not effects.
Safety
Side effects
- Breast pain
- 28.7%
- Mood fluctuation
- 21.9%
- Lower extremity venous thrombosis
- n = 6
- PE
- n = 4
- Stroke
- n = 4
Original publication
Progestogen Experience Among Transgender Women and Gender Diverse Adults Assigned Male at Birth in the United States. Endocr Pract. Published 7 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →